Viewing Study NCT02269293


Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2025-12-31 @ 11:56 PM
Study NCT ID: NCT02269293
Status: COMPLETED
Last Update Posted: 2021-04-23
First Post: 2014-10-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module